Bausch + Lomb Overview

  • Year Founded
  • 1852

Year Founded

  • Status
  • Public

  • Employees
  • 13,300

Employees

  • Stock Symbol
  • BLCO

Stock Symbol

  • Investments
  • 32

  • Share Price
  • $15.05
  • (As of Friday Closing)

Bausch + Lomb General Information

Description

Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Contact Information

Website
www.bausch.com
Formerly Known As
Wp Prism Inc.
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Therapeutic Devices
Other Industries
Surgical Devices
Pharmaceuticals
Stock Exchange
TSE

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bausch + Lomb Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$15.05 $14.90 $13.20 - $21.85 $5.29B 351M 2.53K -$0.96

Bausch + Lomb Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 10,372,122 10,186,746 7,649,493
Revenue 4,314,000 4,146,000 3,768,000 3,765,000
EBITDA 517,000 484,000 592,000 733,000
Net Income (337,000) (260,000) 6,000 182,000
Total Assets 13,293,000 13,442,000 11,144,000 10,823,000
Total Debt 4,584,000 4,562,000 2,436,000 28,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Bausch + Lomb Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Bausch + Lomb‘s full profile, request access.

Request a free trial

Bausch + Lomb Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent
Therapeutic Devices
13,300 As of 2023
00.00
000000000 00.00

00000

eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt
00000000 0000000
Geneva, Switzerland
00000 As of 0000
00.000
000000000 00 00.000

000 00

e irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat n
00000000000 0000000
San Ramon, CA
00000 As of 0000
00.000
000000000 00 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Bausch + Lomb Competitors (7)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alcon Corporate Backed or Acquired Geneva, Switzerland 00000 00.000 000000000 00 00.000
The Cooper Companies Corporation San Ramon, CA 00000 00.000 000000000 00 00.000
RxSight Formerly VC-backed Aliso Viejo, CA 000 00000 00000000 00000
Medtronic Corporation Minneapolis, MN 00000 000.00 000000000 00 000.00
IRIDEX Formerly VC-backed Mountain View, CA 000 000.00 000000000 - 000.00
You’re viewing 5 of 7 competitors. Get the full list »

Bausch + Lomb Patents

Bausch + Lomb Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-D922595-S1 Light therapy device Active 09-Jan-2020 0
US-D940133-S1 Access device Active 09-Jan-2020
US-D928975-S1 Light therapy device Active 09-Jan-2020 0
US-D921212-S1 Light therapy device Active 09-Jan-2020 0
US-20200375681-A1 Detachable finger-activated surgical control device Inactive 03-Jun-2019 A61B17/00
To view Bausch + Lomb’s complete patent history, request access »

Bausch + Lomb Executive Team (41)

Name Title Board Seat Contact Info
Brenton Saunders JD Chief Executive Officer & Chairman
Sam Eldessouky Chief Financial Officer, Finance & Executive Vice President
Al Waterhouse Executive Vice President and Chief Supply Chain and Operations Officer
Frederick Munsch Chief Accounting Officer, Accounting & Controller, Finance
Jonathon Kellerman Chief Compliance Officer
You’re viewing 5 of 41 executive team members. Get the full list »

Bausch + Lomb Board Members (17)

Name Representing Role Since
000000 000 0000000 Self Board Member 000 0000
0000000 00000000 0 Bausch + Lomb Chief Executive Officer & Chairman 000 0000
00000 00000 Self Board Member 000 0000
0000 00 Self Board Member 000 0000
0000 0000000 Self Board Member 000 0000
You’re viewing 5 of 17 board members. Get the full list »

Bausch + Lomb Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bausch + Lomb Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Bausch + Lomb‘s full profile, request access.

Request a free trial

Bausch + Lomb Investments & Acquisitions (32)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Novartis (Eyecare Portfolio) 29-Sep-2023 000000000 00.00 Buildings and Property 0000000 0
Xiidra 29-Sep-2023 0000000000 00.000 Pharmaceuticals 0000000 0
Blink Product Line 06-Jul-2023 0000000000 00000 Other Healthcare Services 000000000
Sanoculis 25-Jan-2023 00000 0000 0000 Surgical Devices 000000 00
AcuFocus 17-Jan-2023 Merger/Acquisition 0000 Therapeutic Devices 000000 00
You’re viewing 5 of 32 investments and acquisitions. Get the full list »

Bausch + Lomb Subsidiaries (6)

Company Name Industry Location Founded
Paragon Bioteck Drug Discovery Portland, OR 2008
AcuFocus Therapeutic Devices Irvine, CA 0000
Total Titanium Medical Supplies Red Bud, IL 0000
Laboratorio Pförtner Cornealent Accessories Buenos Aires, Argentina 0000
Blink Product Line Other Healthcare Services
You’re viewing 5 of 6 subsidiaries. Get the full list »

Bausch + Lomb ESG

Risk Overview

Risk Rating

Updated October, 05, 2023

19.52 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,191

Rank

00.00

Percentile

Healthcare

Industry

00 of 643

Rank

00.00

Percentile

Medical Devices

Subindustry

00 of 58

Rank

00.00

Percentile

To view Bausch + Lomb’s complete esg history, request access »

Bausch + Lomb Exits (4)

Company Name Exit Date Exit Type Exit Size Status Buyers
Cutting Edge Manufacturing 01-Jan-2000 000000000000000000 Completed
  • 000000 + 0000
Miracle-Ear 01-Jan-1993 000000000000000000 Completed
  • 000000 + 0000
Charles River Laboratories International 01-Jan-1984 000000000000000000 Completed
  • 000000 + 0000
Minnesota Eye Consultants Corporate Completed
To view Bausch + Lomb’s complete exits history, request access »

Bausch + Lomb FAQs

  • When was Bausch + Lomb founded?

    Bausch + Lomb was founded in 1852.

  • Who is the founder of Bausch + Lomb?

    John Bausch is the founder of Bausch + Lomb.

  • Who is the CEO of Bausch + Lomb?

    Brenton Saunders JD is the CEO of Bausch + Lomb.

  • What is the size of Bausch + Lomb?

    Bausch + Lomb has 13,300 total employees.

  • What industry is Bausch + Lomb in?

    Bausch + Lomb’s primary industry is Therapeutic Devices.

  • Is Bausch + Lomb a private or public company?

    Bausch + Lomb is a Public company.

  • What is Bausch + Lomb’s stock symbol?

    The ticker symbol for Bausch + Lomb is BLCO.

  • What is the current stock price of Bausch + Lomb?

    As of 14-Jun-2024 the stock price of Bausch + Lomb is $15.05.

  • What is the current market cap of Bausch + Lomb?

    The current market capitalization of Bausch + Lomb is $5.29B.

  • What is Bausch + Lomb’s current revenue?

    The trailing twelve month revenue for Bausch + Lomb is $4.31B.

  • Who are Bausch + Lomb’s competitors?

    Alcon, The Cooper Companies, RxSight, Medtronic, and IRIDEX are some of the 7 competitors of Bausch + Lomb.

  • What is Bausch + Lomb’s annual earnings per share (EPS)?

    Bausch + Lomb’s EPS for 12 months was -$0.96.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »